Single-center kidney paired donation: The methodist San Antonio experience

American Journal of Transplantation

Volumn 12, Issue 8, 2012, Pages 2125-2132

  Bingaman, A W ^a   Wright, F H ^a   Kapturczak, M ^a   Shen, L ^a   Vick, S ^a   Murphey, C L ^b  

^a Methodist Specialty and Transplant Hospital   (United States)

^b Southwest Immunodiagnostics Inc   (United States)

Author keywords

Anti HLA antibodies; desensitization; paired kidney donation; sensitized patients

Indexed keywords

ALEMTUZUMAB; HLA ANTIBODY; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANEL REACTIVE ANTIBODY; PREDNISONE; TACROLIMUS;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLOOD GROUP TYPING; CONTROLLED STUDY; DESENSITIZATION; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; HEALTH PROGRAM; HLA TYPING; HUMAN; KIDNEY DONOR; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY PAIRED DONATION; LIVING DONOR; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE; UNITED STATES;

HISTOCOMPATIBILITY TESTING; HUMANS; KIDNEY TRANSPLANTATION; TEXAS; TISSUE AND ORGAN PROCUREMENT; TREATMENT OUTCOME;

EID: 84864457760     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04070.x     Document Type: Article

References (33)

1. Andreoni KA, Brayman KL, Guidinger MK, Sommers CM, Sung RS,. Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant 2007; 7 (5 Pt 2): 1359-1375.
2. Kaneku HK, Terasaki PI,. Thirty year trend in kidney transplants: UCLA and UNOS Renal Transplant Registry. Clin Transpl 2006: 1-27.
3. Montgomery RA, Zachary AA, Ratner LE, et al,. Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. JAMA 2005; 294: 1655-1663.
4. Vo AA, Lukovsky M, Toyoda M, Wang J, et al,. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242-251.
5. Montgomery RA, Hardy MA, Jordan SC, et al,. Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation 2004; 78: 181-185.
6. Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D,. Intravenous gammaglobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6: 459-466.
7. Gentry SE, Montgomery RA, Segev DL,. Kidney paired donation: Fundamentals, limitations, and expansions. Am J Kidney Dis 57: 144-151.
8. Gentry SE, Segev DL, Simmerling M, Montgomery RA,. Expanding kidney paired donation through participation by compatible pairs. Am J Transplant 2007; 7: 2361-2370.
9. Segev DL, Gentry SE, Warren DS, Reeb B, Montgomery RA,. Kidney paired donation and optimizing the use of live donor organs. JAMA 2005; 293: 1883-1890.
10. UNOS. Organ Procurement and Transplantation Network data. Available at:.
11. Wallis CB, Samy KP, Roth AE, Rees MA,. Kidney paired donation. Nephrol Dial Transplant 26: 2091-2099.
12. Segev DL, Kucirka LM, Gentry SE, Montgomery RA,. Utilization and outcomes of kidney paired donation in the United States. Transplantation 2008; 86: 502-510.
13. de Klerk M, Haase-Kromwijk BJ, Claas FH, Witvliet M, Weimar W,. Living donor kidney exchange for both ABO-incompatible and crossmatch positive donor-recipient combinations. Transplant Proc 2006; 38: 2793-2795.
14. de Klerk M, Haase-Kromwijk BJ, Witvliet M, Claas FH, Weimar W,. Favourable results of the first 2 years of the Dutch paired, living donor, kidney exchange programme. Ned Tijdschr Geneeskd 2007; 151: 130-133.
15. de Klerk M, Keizer KM, Claas FH, Witvliet M, Haase-Kromwijk BJ, Weimar W,. The Dutch national living donor kidney exchange program. Am J Transplant 2005; 5: 2302-2305.
16. de Klerk M, Witvliet MD, Haase-Kromwijk BJ, Claas FH, Weimar W,. Hurdles, barriers, and successes of a national living donor kidney exchange program. Transplantation 2008; 86: 1749-1753.
17. de Klerk M, Witvliet MD, Haase-Kromwijk BJ, Claas FH, Weimar W,. A highly efficient living donor kidney exchange program for both blood type and crossmatch incompatible donor-recipient combinations. Transplantation 2006; 82: 1616-1620.
18. de Klerk M, Witvliet MD, Haase-Kromwijk BJ, Weimar W, Claas FH,. A flexible national living donor kidney exchange program taking advantage of a central histocompatibility laboratory: The Dutch model. Clin Transpl 2008: 69-73.
19. Ferrari P, Woodroffe C, Christiansen FT,. Paired kidney donations to expand the living donor pool: The Western Australian experience. Med J Aust 2009; 190: 700-703.
20. Snary D, Barnstable CJ, Bodmer WF, Crumpton MJ,. Molecular structure of human histocompatibility antigens: The HLA-C series. Eur J Immunol 1977; 7: 580-585.
21. McCutcheon JA, Gumperz J, Smith KD, Lutz CT, Parham P,. Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA. J Exp Med 1995; 181: 2085-2095.
22. Kaplan I, Houp JA, Montgomery RA, Leffell MS, Hart JM, Zachary AA,. A computer match program for paired and unconventional kidney exchanges. Am J Transplant 2005; 5: 2306-2308.
23. Bryan CF, Nelson PW, Shield CF, et al,. Long-term survival of kidneys transplanted from live A2 donors to O and B recipients. Am J Transplant 2007; 7: 1181-1184.
24. Bingaman AW, Wright FH, Murphey CL,. Kidney paired donation in live-donor kidney transplantation. N Engl J Med 363: 1091-1092.
25. Ratner LE, Rana A, Ratner ER, et al,. The altruistic unbalanced paired kidney exchange: Proof of concept and survey of potential donor and recipient attitudes. Transplantation 89: 15-22.
26. Ratner LE, Ratner ER, Kelly J, et al,. Altruistic unbalanced paired kidney exchange at Columbia University/New York-Presbyterian hospital: Rationale and practical considerations. Clin Transpl 2008: 107-112.
27. Denhaerynck K, Steiger J, Bock A, et al,. Prevalence and risk factors of non-adherence with immunosuppressive medication in kidney transplant patients. Am J Transplant 2007; 7: 108-116.
28. Cleemput I, Kesteloot K, Vanrenterghem Y, De Geest S,. The economic implications of non-adherence after renal transplantation. Pharmacoeconomics 2004; 22: 1217-1234.
29. Hanaway MJ, Woodle ES, Mulgaonkar S, et al,. Alemtuzumab induction in renal transplantation. N Engl J Med 364: 1909-1919.
30. Farney AC, Doares W, Rogers J, et al,. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 2009; 88: 810-819.
31. Gloor J, Stegall MD,. Sensitized renal transplant recipients: Current protocols and future directions. Nat Rev Nephrol 2010; 6: 584-593.
32. Gloor JM, Winters JL, Cornell LD, et al,. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 10: 582-589.
33. Rees MA, Kopke JE, Pelletier RP, et al,. A nonsimultaneous, extended, altruistic-donor chain. N Engl J Med 2009; 360: 1096-1101.